- Trials with a EudraCT protocol (33)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
33 result(s) found for: Alectinib.
Displaying page 1 of 2.
EudraCT Number: 2022-003275-42 | Sponsor Protocol Number: MEC-2021-0478 | Start Date*: 2023-04-13 |
Sponsor Name: | ||
Full Title: The influence of different DIets on ALECTinib pharmacokinetics in NSCLC patients; the DIALECT study. | ||
Medical condition: Weight gain is a common side effect of alectinib therapy. Semaglutide could be used as medical anti-obesity drug to prevent alectinib-induced weight gain. Since semaglutide delays gastric emptying,... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004331-37 | Sponsor Protocol Number: BO40336 | Start Date*: 2018-06-21 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS... | ||||||||||||||||||
Medical condition: Completely resected, Stage IB (tumors ≥4 cm) to Stage IIIA, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: LV (Completed) GR (Ongoing) DE (Ongoing) AT (Ongoing) GB (GB - no longer in EU/EEA) PT (Completed) PL (Ongoing) ES (Ongoing) HU (Ongoing) DK (Ongoing) IT (Ongoing) RO (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004239-25 | Sponsor Protocol Number: GO42286 | Start Date*: 2021-05-21 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE I/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF ALECTINIB IN PEDIATRIC PATIENTS WITH ALK FUSION POSITIVE SOLID OR CNS TUMORS FOR WHOM PRIOR TREA... | ||||||||||||||||||
Medical condition: ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) DK (Ongoing) IT (Ongoing) DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002352-36 | Sponsor Protocol Number: BO41929 | Start Date*: 2022-05-02 | |||||||||||
Sponsor Name:F. Hoffmann La Roche Ltd. | |||||||||||||
Full Title: A PHASE II, OPEN-LABEL, SINGLE-ARM DECENTRALIZED HOME-BASED APPROACH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALECTINIB IN LOCALLY ADVANCED OR METASTATIC ALK-POSITIVE SOLID TUMORS | |||||||||||||
Medical condition: Anaplastic lymphoma kinase (ALK)-positive solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001957-29 | Sponsor Protocol Number: Brigatinib-3001 | Start Date*: 2018-12-13 | |||||||||||
Sponsor Name:ARIAD Pharmaceuticals, Inc.(a wholly-owned subsidiary of Takeda Pharmaceutical Ltd.) | |||||||||||||
Full Title: A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive on–Small-Cell Lung Cancer Patients Who Have Progresse... | |||||||||||||
Medical condition: ALK positive Locally Advanced or Metastatic Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) AT (Completed) GR (Prematurely Ended) HR (Ongoing) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003432-25 | Sponsor Protocol Number: GOIRC-01-2020 | Start Date*: 2021-02-09 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | |||||||||||||
Full Title: Phase II, open-label, single-arm, multicenter study to assess the activity and safety of ALectinib as NEO-adjuvant therapy in patients with anaplastic lymphoma kinase-positive (ALK+) locally advanc... | |||||||||||||
Medical condition: patients with ALK-positive potentially resectable locally advanced stage III NSCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000207-24 | Sponsor Protocol Number: BO39694 | Start Date*: 2017-05-16 | ||||||||||||||||
Sponsor Name:Roche Farma S.A.U. que realiza el ensayo en España y que actúa como representante de F.Hoffmann-La Roche Ltd. | ||||||||||||||||||
Full Title: A MULTICENTER, INTERNATIONAL, ROLLOVER STUDY OF ALECTINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE OR REARRANGED DURING TRANSFECTION (RET)-POSITIVE CANCER | ||||||||||||||||||
Medical condition: Anaplastic lymphoma kinase (ALK)-positive or rearranged during transfection (RET)-positive cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) FR (Ongoing) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004133-33 | Sponsor Protocol Number: BO28984 | Start Date*: 2014-07-28 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: RANDOMIZED, MULTICENTER, PHASE III, OPEN LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT NAÏVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER | ||
Medical condition: Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Ongoing) IT (Ongoing) GB (GB - no longer in EU/EEA) PT (Ongoing) ES (Ongoing) DE (Completed) FR (Completed) GR (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-003192-18 | Sponsor Protocol Number: NCT-PMO-1602 | Start Date*: 2021-07-08 | |||||||||||
Sponsor Name:German Cancer Research Center | |||||||||||||
Full Title: Continuous ReAssessment with Flexible ExTension in Rare Malignancies – CRAFT: The NCT PMO-1602 Phase II Trial | |||||||||||||
Medical condition: Metastatic or locally advanced malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000634-29 | Sponsor Protocol Number: MO29750 | Start Date*: 2015-08-10 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS PEMETREXED OR DOCETAXEL IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER PATIENTS PREVIOUSLY TREAT... | ||||||||||||||||||
Medical condition: Anaplastic lymphoma kinase-positive (ALK-positive) non-small cell lung cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Completed) ES (Completed) DE (Completed) SK (Completed) HU (Completed) FR (Completed) PL (Completed) BE (Completed) BG (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001737-13 | Sponsor Protocol Number: 202000251 | Start Date*: 2022-03-01 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: Standard dose alectinib versus Therapeutic Drug Monitoring guided alectinib dosing | |||||||||||||
Medical condition: Non-small cell lung carcinoma with ALK fusion | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002063-17 | Sponsor Protocol Number: ETOP12-17 | Start Date*: 2018-02-19 | |||||||||||
Sponsor Name:ETOP (European Thoracic Oncology Platform) | |||||||||||||
Full Title: A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC | |||||||||||||
Medical condition: Advanced stage RET-rearranged NSCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BE (Ongoing) NL (Completed) SI (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002230-37 | Sponsor Protocol Number: IFCT-1902 | Start Date*: 2019-09-16 | ||||||||||||||||
Sponsor Name:IFCT | ||||||||||||||||||
Full Title: A phase II non-randomized, single group assignment, open-label, multicenter study of efficacy and safety of lORlatinib (PF-06463922) monotherapy after failure of first-line second-generation ALK ki... | ||||||||||||||||||
Medical condition: advanced ALK-positive non-small cell Lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000076-28 | Sponsor Protocol Number: BO29554 | Start Date*: 2017-08-25 | ||||||||||||||||
Sponsor Name:Roche Farma S.A (Soc.Unipersonal) que realiza el ensayo | ||||||||||||||||||
Full Title: A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) HARBORIN... | ||||||||||||||||||
Medical condition: Advanced or metastatic Non-small cell lung cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) PL (Ongoing) BE (Ongoing) DE (Completed) FR (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000635-27 | Sponsor Protocol Number: 2002 | Start Date*: 2018-10-10 | |||||||||||
Sponsor Name:ARIAD Pharmaceuticals, Inc.(a wholly-owned subsidiary of Takeda Pharmaceutical Ltd.) | |||||||||||||
Full Title: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib | |||||||||||||
Medical condition: Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) ES (Completed) AT (Completed) NL (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004149-19 | Sponsor Protocol Number: BO42777 | Start Date*: 2022-05-24 | |||||||||||
Sponsor Name:F. Hoffmann La Roche Ltd. | |||||||||||||
Full Title: A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE I... | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) ES (Ongoing) DE (Ongoing) SE (Trial now transitioned) IT (Ongoing) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003924-22 | Sponsor Protocol Number: ML39349 | Start Date*: 2017-05-03 | ||||||||||||||||
Sponsor Name:ROCHE SAS | ||||||||||||||||||
Full Title: AN OPEN-LABEL, MULTICENTER, SINGLE-ARM, PHASE II STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALECTINIB IN PATIENTS WITH ALK-REARRANGED NON−SMALL CELL LUNG CANCER AFTER DISEASE PROGRESSION ON PRIOR A... | ||||||||||||||||||
Medical condition: ALK-rearranged non-small cell lung cancer (NSCLC) after disease progression on prior ALK inhibitor therapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002504-41 | Sponsor Protocol Number: B7461027 | Start Date*: 2020-07-17 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: Single-Arm Study of Lorlatinib in Participants with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyros... | |||||||||||||
Medical condition: ALK-positive metastatic non-small-cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003040-20 | Sponsor Protocol Number: MX39795 | Start Date*: 2018-06-20 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemoth... | |||||||||||||
Medical condition: Cancer of Unknown Primary Site | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Ongoing) EE (Completed) IE (Completed) DE (Temporarily Halted) CZ (Ongoing) FI (Ongoing) LV (Completed) HU (Ongoing) PL (Completed) FR (Ongoing) ES (Ongoing) BG (Ongoing) PT (Ongoing) HR (Ongoing) NL (Ongoing) DK (Completed) CY (Prematurely Ended) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003974-29 | Sponsor Protocol Number: D6186C00001 | Start Date*: 2019-08-15 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy | |||||||||||||
Medical condition: Advanced Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) NO (Ongoing) DK (Completed) ES (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.